May 2010

CRANBURY, N.J., May 13 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics, today announced results for its third quarter ended March 31, 2010.  Palatin reported a net loss of $2.0 million, or ($0.02) per basic and diluted share for the …

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on May 13, 2010 Read More »

CRANBURY, N.J., May 11 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its third quarter, fiscal year 2010 financial results on Thursday, May 13, 2010 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 13, …

Palatin Technologies, Inc. To Report Fiscal Year 2010 Third Quarter Results; Teleconference and Webcast to be held on May 13, 2010 Read More »

CRANBURY, N.J., May 4 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,709,484, titled “Substituted Melanocortin Receptor-Specific Piperazine Compounds,” today.  The claims in the issued patent relate to small molecule compounds which bind to melanocortin receptors.   Palatin has received Notices of Allowance …

Palatin Technologies, Inc. Issued U.S. Patent and Receives Patent Allowance on Seven Additional Patents Read More »